NanoComposix adds drug manufacturing to services roster

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/greenleaf123)
(Image: Getty/greenleaf123)

Related tags: NanoComposix, CMO, Manufacturing

San Diego, CA-based NanoComposix received its drug manufacturing license which it said will ensure clients are able to use one vendor throughout the product life cycle.

NanoComposix is a nanotechnology development and contract manufacturing organization (CMO) and has been manufacturing nanomaterials for biotech clients under current good manufacturing practices (cGMP) since 2017.

The company recently received its Drug Manufacturing License from the Food and Drug Branch of the State of California Department of Public Health​. 

Dedicated to manufacturing nanomaterial-based medical devices and drugs, the facility includes a qualified ISO 8 cleanroom.

According to the company, “the capability of manufacturing drugs in-house ensures nanoComposix' growing number of clients have the flexibility to utilize one vendor throughout the product life cycle.”

Founder and President Dr. Steve Oldenburg said in a statement: "This opens up a new set of capabilities for our clients and allows us to align with our long-term corporate goal of supplying nanotechnology enabled products from concept through commercialization."

Since 2004, NanoComposix has been providing development, fabrication, processing, and scale-up services to commercialize nanomaterials in several applications, including in vitro​ diagnostics, therapeutics, devices, plasmonic, and preclinical drugs. 

Related news

Show more

Related products

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more